D. Weilert

发表

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers

R. Plummer, Karen So, T. Yap, 2018, Journal of clinical pharmacology.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Karen So, A. Dingemans, Yuh-Min Chen, 2018, British journal of clinical pharmacology.

Special Population Studies (Healthy Patient Studies)

D. Weilert, 2010 .

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR‐Mutated Non–Small Cell Lung Cancer

Sang-We Kim, V. Moreno, E. Calvo, 2019, Journal of clinical pharmacology.

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects

N. Goel, R. Reeve, J. Caminis, 2018, Pharmacology research & perspectives.

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

A. Ravaud, B. Keam, N. Penel, 2020, Pharmacology research & perspectives.

Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

Karen So, J. Vansteenkiste, P. Dickinson, 2018, British journal of clinical pharmacology.

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and 1 rosuvastatin 2

J. Vansteenkiste, K. Vishwanathan, D. Weilert, 2019 .

Effect of multiple-dose osimertinib (AZD9291) on the pharmacokinetics (PK) of simvastatin and rosuvastatin.

Karen So, J. Vansteenkiste, P. Dickinson, 2016 .

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects

D. Parasrampuria, K. Brown, J. Maa, 2015, Clinical Drug Investigation.

Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291

R. Plummer, Karen So, E. Lisbon, 2015 .